Literature DB >> 20602168

Impact of heart failure on the incidence of contrast-induced nephropathy in patients with chronic kidney disease.

Jordan L Rosenstock1, Emmanuelle Gilles, Ari B Geller, Georgia Panagopoulos, Staicy Mathew, Deepa Malieckal, Maria V DeVita, Michael F Michelis.   

Abstract

We randomized patients with chronic kidney disease (serum creatinine ≥ 1.5 mg/dl or glomerular filtration rate (GFR) <60 ml/min/1.73 m²) in a double-blind fashion to receive saline or sodium bicarbonate prior to and after cardiac or vascular angiography. The primary endpoint was contrast-induced nephropathy (CIN), defined as an increase in serum creatinine by 25% or by 0.5 mg/dl from baseline. Patients with congestive heart failure (CHF), cardiac ejection fraction (EF) <30%, or GFR < 20 ml/min/1.73 m² were excluded. The study was discontinued (after 142 patients were randomized) due to a low incidence of CIN (1.5%). We retrospectively identified all cases of CIN (n = 30) at our institution during the same time period to see if these patients differed from our trial sample. There was no difference in serum creatinine (1.7 ± 0.4 vs. 1.7 ± 0.6 mg/dL), GFR (42.7 ± 9.7 vs. 45.3 ± 3.2 ml/min), incidence of diabetes (51.8% vs. 63.3%), contrast volume (121.7 ± 63.8 vs. 122.7 ± 68.3 ml), ACE inhibitor or angiotensin receptor blocker use (54.0% vs 63.3%), and periprocedure diuretic use (33.1% vs 26.7%). On multivariate analysis, only a cardiac ejection fraction (EF) of less than 40% was significantly associated with CIN (odds ratio, 4.52; 95% confidence interval, 1.30-15.71; P = 0.02). In all, 22/30 patients (73.3%) who developed CIN had at least one or more characteristics that would have excluded their enrollment in our randomized trial including evidence of congestive heart failure (17/30 patients), EF less than 30% (9 patients), age greater than 85 years (2 patients), or advanced renal failure with a baseline GFR of less than 20 cc/min (1 patient). In summary, patients with CKD without evidence of CHF who receive adequate hydration appear to have a very low risk of CIN associated with angiography. A low EF (less than 40%) appeared to be the most significant risk factor for CIN in our population.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20602168     DOI: 10.1007/s11255-010-9798-4

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  20 in total

1.  Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables.

Authors:  George Dangas; Ioannis Iakovou; Eugenia Nikolsky; Eve D Aymong; Gary S Mintz; Nicholas N Kipshidze; Alexandra J Lansky; Issam Moussa; Gregg W Stone; Jeffrey W Moses; Martin B Leon; Roxana Mehran
Journal:  Am J Cardiol       Date:  2005-01-01       Impact factor: 2.778

Review 2.  Prophylaxis strategies for contrast-induced nephropathy.

Authors:  Neesh Pannu; Natasha Wiebe; Marcello Tonelli
Journal:  JAMA       Date:  2006-06-21       Impact factor: 56.272

3.  Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies.

Authors:  Carlo Briguori; Flavio Airoldi; Davide D'Andrea; Erminio Bonizzoni; Nuccia Morici; Amelia Focaccio; Iassen Michev; Matteo Montorfano; Mauro Carlino; John Cosgrave; Bruno Ricciardelli; Antonio Colombo
Journal:  Circulation       Date:  2007-02-19       Impact factor: 29.690

4.  A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.

Authors:  A S Levey; J P Bosch; J B Lewis; T Greene; N Rogers; D Roth
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

Review 5.  Systematic review: sodium bicarbonate treatment regimens for the prevention of contrast-induced nephropathy.

Authors:  Sophia Zoungas; Toshiharu Ninomiya; Rachel Huxley; Alan Cass; Meg Jardine; Martin Gallagher; Anushka Patel; Ali Vasheghani-Farahani; Gelareh Sadigh; Vlado Perkovic
Journal:  Ann Intern Med       Date:  2009-11-03       Impact factor: 25.391

6.  Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial.

Authors:  Somjot S Brar; Albert Yuh-Jer Shen; Michael B Jorgensen; Adam Kotlewski; Vicken J Aharonian; Natasha Desai; Michael Ree; Ahmed Ijaz Shah; Raoul J Burchette
Journal:  JAMA       Date:  2008-09-03       Impact factor: 56.272

7.  Sodium bicarbonate versus saline for the prevention of contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention.

Authors:  Mauro Maioli; Anna Toso; Mario Leoncini; Michela Gallopin; Delio Tedeschi; Carlo Micheletti; Francesco Bellandi
Journal:  J Am Coll Cardiol       Date:  2008-08-19       Impact factor: 24.094

8.  Sodium bicarbonate for the prevention of contrast-induced nephropathy: a meta-analysis of 17 randomized trials.

Authors:  Mehmet Kanbay; Adrian Covic; Steven G Coca; Faruk Turgut; Ali Akcay; Chirag R Parikh
Journal:  Int Urol Nephrol       Date:  2009-04-25       Impact factor: 2.370

9.  Early effects of contrast media on renal hemodynamics and tubular function in chronic renal failure.

Authors:  D Russo; R Minutolo; B Cianciaruso; B Memoli; G Conte; L De Nicola
Journal:  J Am Soc Nephrol       Date:  1995-11       Impact factor: 10.121

10.  A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation.

Authors:  Roxana Mehran; Eve D Aymong; Eugenia Nikolsky; Zoran Lasic; Ioannis Iakovou; Martin Fahy; Gary S Mintz; Alexandra J Lansky; Jeffrey W Moses; Gregg W Stone; Martin B Leon; George Dangas
Journal:  J Am Coll Cardiol       Date:  2004-10-06       Impact factor: 24.094

View more
  19 in total

1.  Does N-terminal pro-brain natriuretic peptide add prognostic value to the Mehran risk score for contrast-induced nephropathy and long-term outcomes after primary percutaneous coronary intervention?

Authors:  Yuan-Hui Liu; Lei Jiang; Ji-Yan Chen; Ning Tan; Yong Liu; Peng Cheng He
Journal:  Int Urol Nephrol       Date:  2016-07-29       Impact factor: 2.370

2.  Diastolic dysfunction and contrast-induced nephropathy in patients undergoing coronary angiography.

Authors:  S Acikel; R Akdemir; H Kilic; G Cagirci; M Dogan; A B Yesilay; E Yeter
Journal:  Herz       Date:  2014-11-30       Impact factor: 1.443

3.  Prevention of contrast-induced nephropathy by adequate hydration combined with isosorbide dinitrate for patients with renal insufficiency and congestive heart failure.

Authors:  Geng Qian; Chang-Fu Liu; Jun Guo; Wei Dong; Jin Wang; Yundai Chen
Journal:  Clin Cardiol       Date:  2019-01-07       Impact factor: 2.882

4.  The contrast medium volume to estimated glomerular filtration rate ratio as a predictor of contrast-induced nephropathy after primary percutaneous coronary intervention.

Authors:  Yong Liu; Ning Tan; Ying-Ling Zhou; Peng-Cheng He; Jian-Fang Luo; Ji-Yan Chen
Journal:  Int Urol Nephrol       Date:  2011-02-20       Impact factor: 2.370

5.  Prevention of contrast-induced nephropathy with prostaglandin E1 in high-risk patients undergoing percutaneous coronary intervention.

Authors:  Wen-Hua Li; Dong-Ye Li; Wen-Hao Qian; Jia-Li Liu; Tong-Da Xu; Hong Zhu; Hai-Yan He
Journal:  Int Urol Nephrol       Date:  2014-02-26       Impact factor: 2.370

6.  Predictive value of GRACE risk scores for contrast-induced acute kidney injury in patients with ST-segment elevation myocardial infarction before undergoing primary percutaneous coronary intervention.

Authors:  Yuan Hui Liu; Yong Liu; Ning Tan; Ji-Yan Chen; Jin Chen; Shao-Hui Chen; Yi-Ting He; Peng Ran; Piao Ye; Yun Li
Journal:  Int Urol Nephrol       Date:  2013-11-22       Impact factor: 2.370

Review 7.  Prevention of contrast-induced AKI: a review of published trials and the design of the prevention of serious adverse events following angiography (PRESERVE) trial.

Authors:  Steven D Weisbord; Martin Gallagher; James Kaufman; Alan Cass; Chirag R Parikh; Glenn M Chertow; Kendrick A Shunk; Peter A McCullough; Michael J Fine; Maria K Mor; Robert A Lew; Grant D Huang; Todd A Conner; Mary T Brophy; Joanne Lee; Susan Soliva; Paul M Palevsky
Journal:  Clin J Am Soc Nephrol       Date:  2013-05-09       Impact factor: 8.237

8.  Preprocedural N-terminal pro-brain natriuretic peptide (NT-proBNP) is similar to the Mehran contrast-induced nephropathy (CIN) score in predicting CIN following elective coronary angiography.

Authors:  Yong Liu; Yi-ting He; Ning Tan; Ji-yan Chen; Yuan-hui Liu; Da-hao Yang; Shui-jin Huang; Piao Ye; Hua-long Li; Peng Ran; Chong-yang Duan; Shi-qun Chen; Ying-ling Zhou; Ping-yan Chen
Journal:  J Am Heart Assoc       Date:  2015-04-17       Impact factor: 5.501

9.  Association of N-terminal pro-B-type natriuretic peptide with contrast-induced nephropathy and long-term outcomes in patients with chronic kidney disease and relative preserved left ventricular function.

Authors:  Yuan-hui Liu; Yong Liu; Ying-ling Zhou; Dan-qing Yu; Peng-cheng He; Nian-jin Xie; Hua-long Li; Ji-yan Chen; Ning Tan
Journal:  Medicine (Baltimore)       Date:  2015-04       Impact factor: 1.889

10.  Impact of anemia on contrast-induced nephropathy (CIN) in patients undergoing percutaneous coronary interventions.

Authors:  Wen-hua Li; Dong-ye Li; Fei Han; Tong-da Xu; Yang-bing Zhang; Hong Zhu
Journal:  Int Urol Nephrol       Date:  2012-12-07       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.